Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD). 

Biotechnology

Vanqua Bio

Jim Sullivan

Jesse Cedarbaum

Omer Siddiqui

Daniel Ysselstein

Jack Beyer

Kevin Hunt

The Research and Development team at Vanqua Bio is dedicated to advancing innovative therapies for neurodegenerative diseases through cutting-edge drug discovery and development. This multidisciplinary team, comprising experts in cell and molecular pharmacology, medicinal chemistry, and scientific research, collaborates to identify and validate genetic targets, develop in vitro disease models, and ultimately translate scientific findings into transformative treatments for conditions like Parkinson’s, Alzheimer’s, ALS, and Gaucher disease.

Research and Development

Leadership Team

Research and Development Team

Research and Development

About

Team members

Other teams at Vanqua Bio

Leadership Team

Research and Development Team